Close this search box.


These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.


  • Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009;61:198–223. (PDF)
  • Pasternak B, Aspenberg P. Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. Acta Orthop 2009;80:693–703. (PDF)
  • Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol 2010;6:26–715. (PDF)
  • Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001,33:33–44. (PDF)


  • Forrester HB, Temple-Smith P, Ham S, de Kretser D, Southwick G, Sprung CN. Genome-Wide Analysis Using Exon Arrays Demonstrates an Important Role for Expression of Extra-Cellular Matrix, Fibrotic Control and Tissue Remodelling Genes in Dupuytren’s Disease. PLoS One 2013;8:e59056. (PDF)
  • Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, Clark IM. A Complete Expression Profile of Matrix-Degrading Metalloproteinases in Dupuytren’s Disease. J Hand Surg Am 2007;32:343–51. (PDF)
  • Johnston P, Larson D, Clark IM, Chojnowski AJ. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren’s disease.  J Hand Surg Am 2008;33:1160–7. (PDF)
  • Wilkinson JM, Davidson RK, Swingler TE, Jones ER, Corps AN, Johnston P, et al. MMP-14 and MMP-2 are key metalloproteases in Dupuytren’s disease fibroblast-mediated contraction. Biochim Biophys Acta – Mol Basis Dis 2012;1822:897–905. (PDF)